Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2023B (Omicron XBB.1.5) Booster vs SCB-2019 in COVID-19 Vaccinated Adults
NCT06567457Phase 3Withdrawn
- Sponsor
- Clover Biopharmaceuticals
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Vaccine mRNA, mRNA Vaccines, Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of SCB-2023 in coronavirus disease 2019 (COVID-19), sponsored by Clover Biopharmaceuticals. Planned start Oct 2023; status: withdrawn.
02
Drugs
SCB-2023
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06567457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567457.